Literature DB >> 26714953

Factors Affecting the Completion of Adjuvant Chemotherapy in Early-Stage Breast Cancer.

Sylvia A Reyes1, Tari A King1, Kezhen Fei2, Rebeca Franco2, Nina A Bickell3.   

Abstract

BACKGROUND: Despite the survival benefit associated with adjuvant chemotherapy in early-stage breast cancer, many do not complete treatment. This study identified factors associated with noncompletion of adjuvant chemotherapy among a select population of women with early-stage breast cancer.
METHODS: The study sample was obtained from a multicenter study designed to evaluate patient-assistance program usage among early-stage breast cancer patients requiring adjuvant therapy. In this study, 333 patients with stages I and II breast cancer undergoing surgery from October 2006 to September 2009 completed 6-month follow-up surveys assessing their experiences with care, health status, social support, self-efficacy, and treatment beliefs. In- and outpatient medical records were abstracted to assess treatment completion. Of the 333 patients, 198 initiated adjuvant chemotherapy and formed our study cohort. The study compared patients who did and did not complete adjuvant chemotherapy.
RESULTS: The median patient age was 53 years (range 28-86 years). According to self-identification, 41 % of the patients were non-Hispanic white and 21 % were black. A total of 13 patients (7 %) did not complete adjuvant chemotherapy. In the bivariate analysis, the patients not completing chemotherapy were more likely to be black and unmarried women with low emotional social support and a poor body image after treatment. In the multivariate analysis, black race [odds ratio (OR) 5.62; 95 % confidence interval (CI) 1.63-20.36] and poor body image (OR 9.75; 95 % CI 2.12-95.95) were independently associated with noncompletion of chemotherapy.
CONCLUSIONS: Overall chemotherapy noncompletion rates were low among women exposed to patient-assistance programs. However, poor body image and black race were independent predictors of uncompleted chemotherapy. The true impact of race in this group may result from social factors that occur more often among black women, including poor social support.

Entities:  

Mesh:

Year:  2015        PMID: 26714953     DOI: 10.1245/s10434-015-5039-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis.

Authors:  Angela K Green; Emeline M Aviki; Konstantina Matsoukas; Sujata Patil; Deborah Korenstein; Victoria Blinder
Journal:  Breast Cancer Res Treat       Date:  2018-08-09       Impact factor: 4.872

2.  Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.

Authors:  Stella Stergiopoulos; Mortiz Fehrle; Patrick Caubel; Louise Tan; Louise Jebson
Journal:  Pharmaceut Med       Date:  2019-12

3.  Social Determinants of Racial Disparities in Breast Cancer Mortality Among Black and White Women.

Authors:  Oluwole Adeyemi Babatunde; Jan M Eberth; Tisha Felder; Robert Moran; Samantha Truman; James R Hebert; Jiajia Zhang; Swann Arp Adams
Journal:  J Racial Ethn Health Disparities       Date:  2020-05-08

4.  Race, ethnicity and risk of second primary contralateral breast cancer in the United States.

Authors:  Gordon P Watt; Esther M John; Elisa V Bandera; Kathleen E Malone; Charles F Lynch; Julie R Palmer; Julia A Knight; Melissa A Troester; Jonine L Bernstein
Journal:  Int J Cancer       Date:  2021-02-24       Impact factor: 7.316

5.  Compliance with multidisciplinary team recommendations and disease outcomes in early breast cancer patients: An analysis of 4501 consecutive patients.

Authors:  Xingxia Yang; Jiahui Huang; Xiaoping Zhu; Kunwei Shen; Juanying Zhu; Xiaosong Chen
Journal:  Breast       Date:  2020-05-28       Impact factor: 4.380

6.  Race and Ethnicity Influence Survival Outcomes in Women of Caribbean Nativity With Epithelial Ovarian Cancer.

Authors:  Matthew Schlumbrecht; Danielle Cerbon; Melissa Castillo; Scott Jordan; Raleigh Butler; Andre Pinto; Sophia George
Journal:  Front Oncol       Date:  2020-05-29       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.